Mohammed Elmujtba Adam Essa1*, Maha Elnigoumi2, Shaima N Elgenaid3*, Noha Ibrahim Ahmed Eltahir4, Ziryab Imad Taha Mahmoud1,5, Mustafa Mohamed Ali Hussein1, Mutwaly Defealla Yousif Haron1, Abdelkareem A Ahmed1,6* and Elnour Mohammed Elagib4
1Departments of Clinical Medicine, Medical and Cancer Research Institute (MCRI), Nyala, Sudan
2Department of Geriatric, Queen’s Medical Center, Nottingham University hospital, Nottingham, UK
3Faculty of Medicine, University of Khartoum, Khartoum, Sudan
4Department of Medicine and Rheumatology, Omdurman Military Hospital, Sudan
5Department of Internal Medicine, Faculty of Medicine, University of Bahri, Khartoum, Sudan
6Department of Physiology and Biochemistry, Faculty of Veterinary Science, University of Nyala, Nyala, Sudan
7Institute of Molecular Biology, University of Nyala, Nyala, Sudan
*Corresponding Author: Mohammed Elmujtba Adam Essa, Departments of Clinical Medicine, Medical and Cancer Research Institute (MCRI), Nyala, Sudan. E-mail: firstname.lastname@example.org; Abdelkareem Abdallah Ahmed, Department of Physiology and Biochemistry, Faculty of Veterinary Science, University of Nyala, Nyala, Nyala, Sudan E-mail: email@example.com; Shaima N Elgenaid, Department of Internal Medicine, Faculty of Medicine, University of Khartoum, Khartoum, Sudan, E-mail: firstname.lastname@example.org
Received: December 03, 2019; Published: February 21, 2020
Systemic Lupus Erythematosus (SLE) is a disease with various manifestations. Its treatment aims to reduce the symptoms and to prevent the flairs. In this report, we are discussing three cases of SLE who required treatment with Rituximab. The first case was an 18 year old female who presented with urinary symptoms and subsequently she developed lupus nephritis. She was treated with prednisolone and hydroxychloroquine for two months without response. The Rituximab was introduced with a good initial response. The second case was a 20 year female, presented with nonspecific symptoms. She was treated with steroid but her condition was complicated by development of antiphospholipid antibodies, abortion and lupus nephritis. The last case also developed lupus nephritis despite the treatment with steroid and hydroxychloroquine. Rituximab was add but discontinued because the patient was financial unaffordable to provide the rest of the doses. Her condition deteriorated more and ultimately died.
Keywords: Biologic Treatment; Rituximab; Sudanese; Systemic Lupus Erythematosus
Citation: Mohammed Elmujtba Adam Essa., et al. “Decision to Use Rituximab as a Systemic Biological Treatment in Systemic Lupus Erythmatosus Among Sudanese Patients: Case Serious Report”. Acta Scientific Women's Health 2.3 (2020): 01-06.
Copyright: © 2020 Mohammed Elmujtba Adam Essa., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.